Day: 14. July 2021

14-7 Novo Nordisk takes license from Heartseed Japan for iPS-derived cardiomyocytes

Heartseed has granted Novo the exclusive rights to develop, manufacture, and sell HS-001, regenerated cardiomyocytes derived from heterologous iPS cells in the world except Japan. In Japan, Heartseed will continue to develop the product independently, while retaining the rights to develop, manufacture and market it. After obtaining approval, Heartseed will market the product jointly with […]

Scroll to top